Long-term results back FemSoft urinary insert:
This article was originally published in Clinica
Executive Summary
A one to two year follow-up study from an ongoing trial of Rochester Medical's FemSoft female, single-use stress urinary incontinence device has produced positive results. Interim data from the five year, 150-patient trial indicate a statistically significant reduction in both incontinence episodes and amount of urine loss in patients using the FDA-approved FemSoft insert, notes the Stewartville, Minnesota firm. Notably, some 81% of patients reported that they never or rarely experienced incontinence while using the device. The findings appear in the International Urogynecology Journal (May).
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.